Advanced Filters
noise

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 807 clinical trials

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease …

18 years of age All Phase 2/3
Z Zhiqi Mao, Ph.D

Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease

To investigate the safety of deep brain stimulation (DBS) and cervical deep lymphoid-venous anastomosis (LVA) in the treatment of severe Alzheimer's disease (AD); to investigate the effectiveness of DBS and LVA in the treatment of severe AD, i.e., effects of deep brain stimulation on cognitive function, emotion and life quality …

40 - 80 years of age All Phase 1

Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease

The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explore whether the combined treatment shows promise …

65 - 85 years of age All Phase N/A
Y Yixun HAN

Identifying Biomarkers in Alzheimer's Disease

Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is …

20 years of age All Phase N/A

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.

65 - 90 years of age All Phase N/A
E Enrique Vargas, MD

Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to …

55 - 89 years of age All Phase N/A
H Harry Chung

Open-Label Extension Protocol to SNK01-AD01 Study

Open-Label Extension Protocol to SNK01-AD01 Study

40 - 85 years of age All Phase 2
Y Yi Tang, M.D., Ph.D.

Clinical Analgesic Management in Dementia

This study is designed to assess the efficacy and safety of oxycodone in managing moderate to severe pain in patients with Alzheimer's disease. The trial will be conducted at Xuanwu Hospital, Capital Medical University, and will enroll 10 eligible participants. Participants will receive oxycodone/acetaminophen (5 mg/325 mg) once daily for …

50 - 90 years of age All Phase 3

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. …

50 years of age All Phase N/A

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

50 - 75 years of age All Phase 1

Simplify language using AI